Chip stocks lift Kospi above 7,130; Nikkei edges up despite yen pressure
South Korea's Kospi jumped over 1.9% on chip strength, while Japan's Nikkei barely rose after weathering a yen spike.
US stock futures fell as bond yields continued to climb, with the 10-year yield hitting its highest since October 2023.
Wall Street faces another negative session, as pre-market indicators signal declines. S&P 500 futures slipped 0.3%, while Nasdaq futures fell 0.6% before the opening bell.
This week's decline remains relatively modest compared to the August rally, but caution prevails as global bond yields have surged over the past week.
For some context: a tectonic shift is taking place in the bond market.
The 10-year US Treasury yield climbed to 4.81%, its highest since October 2023, with yields in Europe and Japan also rising sharply.
This is not a single event but a broader trend, which could unsettle wider markets.
Equities generally react negatively to rising yields, and the problem intensifies when the rise stems from inflation or fiscal worries, as is the case now.
Investors then require a higher risk premium, increasing the opportunity cost of holding expensive stocks. Tech shares, in particular, see their valuations and earnings multiples questioned, making them more sensitive to yield increases.
Wall Street's decline this week has been relatively limited so far, despite the expected losses at the open. However, if bond yields keep climbing further, a sharper selloff in stocks could be imminent.
Stay tuned for further developments.
Share to
Disclaimer: this article comes from third-party media and is provided for reference only. It does not constitute investment advice. Crypto and other financial products carry significant price volatility risk, so please make your own decisions carefully.
South Korea's Kospi jumped over 1.9% on chip strength, while Japan's Nikkei barely rose after weathering a yen spike.
South Korean stocks rallied, led by Samsung and SK Hynix, while Wall Street futures declined amid inflation concerns and higher oil prices.
Analysts see Tempus AI benefiting from personalized cancer vaccines, with potential $600M annual sequencing revenue.
Goldman Sachs says India has weathered external shocks, with MSCI India forward P/E at a decade low of 20x and earnings growth forecast at 12%.